Cambridge biotech Alchemab Therapeutics has extended its Series A round with a £25 million ($34 million) investment from the British Business Bank, which the company says is the state-owned lender’s largest backing of a life sciences company to date. The money will help the clinical-stage firm build its drug pipeline and expand a proprietary antibody […]

This story continues at The Next Web